All of DSpace

Browsing by Subject "multiple myeloma"

Now showing items 1-15 of 15

    • Anti-cd20 agents for multiple sclerosis: Spotlight on ocrelizumab and ofatumumab 

      Florou D., Katsara M., Feehan J., Dardiotis E., Apostolopoulos V. (2020)
      Until recently, in the pathogenesis of Multiple Sclerosis (MS), the contribution of B cells has been largely underestimated, and the disease was considered a T-cell-mediated disorder. However, newer evidence shows that B ...

    • Association of interleukin-1A, interleukin-1B and interleukin-1 receptor antagonist gene polymorphisms with multiple myeloma 

      Abazis-Stamboulieh, D.; Oikonomou, P.; Papadoulis, N.; Panayiotidis, P.; Vrakidou, E.; Tsezou, A. (2007)
      Interleukin-1 (IL-1) is a cytokine involved in the maturation and proliferation of B cells and plays a significant role in the development of lytic bone lesions, a major clinical feature of multiple myeloma (MM) patients. ...

    • Current status and future prospects of small–molecule protein–protein interaction (PPI) inhibitors of tumor necrosis factor (TNF) and receptor activator of NF-κB ligand (RANKL) 

      Melagraki G., Leonis G., Ntougkos E., Rinotas V., Papaneophytou C., Mavromoustakos T., Kontopidis G., Douni E., Kollias G., Afantitis A. (2018)
      The overexpression of Tumor Necrosis Factor (TNF) is directly related to the development of several autoimmune diseases, such as rheumatoid and psoriatic arthritis, inflammatory bowel disease, Crohn’s disease, refractory ...

    • Depression, anxiety and stress among patients with hematological malignancies and the association with quality of life: A cross-sectional study 

      Papathanasiou I.V., Kelepouris K., Valari C., Papagiannis D., Tzavella F., Kourkouta L., Tsaras K., Fradelos E.C. (2020)
      Aim. To evaluate psychological distress and quality of life of patients with hematological malignancies, as well as to identify the prognostic factors that aggravate their condition. Methods. A cross-sectional, descriptive ...

    • Endothelin-1 (ET-1) induces resistance to bortezomib in human multiple myeloma cells via a pathway involving the ETB receptor and upregulation of proteasomal activity 

      Vaiou M., Pangou E., Liakos P., Sakellaridis N., Vassilopoulos G., Dimas K., Papandreou C. (2016)
      Purpose: Bortezomib (BTZ) is used for the treatment of multiple myeloma (MM). However, a significant proportion of patients may be refractory to the drug. This study aimed to investigate whether the endothelin (ET-1) axis ...

    • Global, regional, and national age-sex specifc mortality for 264 causes of death, 1980-2016: A systematic analysis for the Global Burden of Disease Study 2016 

      Naghavi M., Abajobir A.A., Abbafati C., Abbas K.M., Abd-Allah F., Abera S.F., Aboyans V., Adetokunboh O., Ärnlöv J., Afshin A., Agrawal A., Kiadaliri A.A., Ahmadi A., Ahmed M.B., Aichour A.N., Aichour I., Aichour M.T.E., Aiyar S., Al-Eyadhy A., Alahdab F., Al-Aly Z., Alam K., Alam N., Alam T., Alene K.A., Ali S.D., Alizadeh-Navaei R., Alkaabi J.M., Alkerwi A., Alla F., Allebeck P., Allen C., Al-Raddadi R., Alsharif U., Altirkawi K.A., Alvis-Guzman N., Amare A.T., Amini E., Ammar W., Amoako Y.A., Anber N., Andersen H.H., Andrei C.L., Androudi S., Ansari H., Antonio C.A.T., Anwari P., Arora M., Artaman A., Aryal K.K., Asayesh H., Asgedom S.W., Atey T.M., Avila-Burgos L., Avokpaho E.F.G.A., Awasthi A., Quintanilla B.P.A., Béjot Y., Babalola T.K., Bacha U., Balakrishnan K., Barac A., Barboza M.A., Barker-Collo S.L., Barquera S., Barregard L., Barrero L.H., Baune B.T., Bedi N., Beghi E., Bekele B.B., Bell M.L., Bennett J.R., Bensenor I.M., Berhane A., Bernabé E., Betsu B.D., Beuran M., Bhatt S., Biadgilign S., Bienhof K., Bikbov B., Bisanzio D., Bourne R.R.A., Breitborde N.J.K., Bulto L.N.B., Bumgarner B.R., Butt Z.A., Cárdenas R., Cahuana-Hurtado L., Cameron E., Campuzano J.C., Car J., Carrero J.J., Carter A., Casey D.C., Castañeda-Orjuela C.A., Catalá-López F., Charlson F.J., Chibueze C.E., Chimed-Ochir O., Chisumpa V.H., Chitheer A.A., Christopher D.J., Ciobanu L.G., Cirillo M., Cohen A.J., Colombara D., Cooper C., Cowie B.C., Criqui M.H., Dandona L., Dandona R., Dargan P.I., Das Neves J., Davitoiu D.V., Davletov K., De Courten B., Degenhardt L., Deiparine S., Deribe K., Deribew A., Dey S., Dicker D., Ding E.L., Djalalinia S., Do H.P., Doku D.T., Douwes-Schultz D., Driscoll T.R., Dubey M., Duncan B.B., Echko M., El-Khatib Z.Z., Ellingsen C.L., Enayati A., Erskine H.E., Eskandarieh S., Esteghamati A., Ermakov S.P., Estep K., Sa Farinha C.S., Faro A., Farzadfar F., Feigin V.L., Fereshtehnejad S.-M., Fernandes J.C., Ferrari A.J., Feyissa T.R., Filip I., Finegold S., Fischer F., Fitzmaurice C., Flaxman A.D., Foigt N., Frank T., Fraser M., Fullman N., Fürst T., Furtado J.M., Gakidou E., Garcia-Basteiro A.L., Gebre T., Gebregergs G.B., Gebrehiwot T.T., Gebremichael D.Y., Geleijnse J.M., Genova-Maleras R., Gesesew H.A., Gething P.W., Gillum R.F., Ginawi I.A.M., Giref A.Z., Giroud M., Giussani G., Godwin W.W., Gold A.L., Goldberg E.M., Gona P.N., Gopalani S.V., Gouda H.N., Goulart A.C., Griswold M., Gupta P.C., Gupta R., Gupta T., Gupta V., Haagsma J.A., Hafezi-Nejad N., Hailu A.D., Hailu G.B., Hamadeh R.R., Hambisa M.T., Hamidi S., Hammami M., Hancock J., Handal A.J., Hankey G.J., Hao Y., Harb H.L., Hareri H.A., Hassanvand M.S., Havmoeller R., Hay S.I., He F., Hedayati M.T., Henry N.J., Heredia-Pi I.B., Herteliu C., Hoek H.W., Horino M., Horita N., Hosgood H.D., Hostiuc S., Hotez P.J., Hoy D.G., Huynh C., Iburg K.M., Ikeda C., Ileanu B.V., Irenso A.A., Irvine C.M.S., Jürisson M., Jacobsen K.H., Jahanmehr N., Jakovljevic M.B., Javanbakht M., Jayaraman S.P., Jeemon P., Jha V., John D., Johnson C.O., Johnson S.C., Jonas J.B., Kabir Z., Kadel R., Kahsay A., Kamal R., Karch A., Karimi S.M., Karimkhani C., Kasaeian A., Kassaw N.A., Kassebaum N.J., Katikireddi S.V., Kawakami N., Keiyoro P.N., Kemmer L., Kesavachandran C.N., Khader Y.S., Khan E.A., Khang Y.-H., Khoja A.T.A., Khosravi A., Khosravi M.H., Khubchandani J., Kieling C., Kievlan D., Kim D., Kim Y.J., Kimokoti R.W., Kinfu Y., Kissoon N., Kivimaki M., Knudsen A.K., Kopec J.A., Kosen S., Koul P.A., Koyanagi A., Defo B.K., Kulikof X.R., Kumar G.A., Kumar P., Kutz M., Kyu H.H., Lal D.K., Lalloo R., Lambert T.L.N., Lan Q., Lansingh V.C., Larsson A., Lee P.H., Leigh J., Leung J., Levi M., Li Y., Kappe D.L., Liang X., Liben M.L., Lim S.S., Liu A., Liu P.Y., Liu Y., Lodha R., Logroscino G., Lorkowski S., Lotufo P.A., Lozano R., Lucas T.C.D., Ma S., Macarayan E.R.K., Maddison E.R., Abd El Razek M.M., Majdan M., Majdzadeh R., Majeed A., Malekzadeh R., Malhotra R., Malta D.C., Manguerra H., Manyazewal T., Mapoma C.C., Marczak L.B., Markos D., Martinez-Raga J., Martins-Melo F.R., Martopullo I., McAlinden C., McGaughey M., McGrath J.J., Mehata S., Meier T., Meles K.G., Memiah P., Memish Z.A., Mengesha M.M., Mengistu D.T., Menota B.G., Mensah G.A., Meretoja A., Meretoja T.J., Millear A., Miller T.R., Minnig S., Mirarefn M., Mirrakhimov E.M., Misganaw A., Mishra S.R., Mohammad K.A., Mohammadi A., Mohammed S., Mokdad A.H., Mola G.L.D., Mollenkopf S.K., Molokhia M., Monasta L., Hernandez J.C.M., Montico M., Mooney M.D., Moradi-Lakeh M., Moraga P., Morawska L., Morrison S.D., Morozof C., Mountjoy-Venning C., Mruts K.B., Muller K., Murthy G.V.S., Musa K.I., Nachega J.B., Naheed A., Naldi L., Nangia V., Nascimento B.R., Nasher J.T., Natarajan G., Negoi I., Ngunjiri J.W., Nguyen C.T., Nguyen G., Nguyen M., Nguyen Q.L., Nguyen T.H., Nichols E., Ningrum D.N.A., Nong V.M., Noubiap J.J.N., Ogbo F.A., Oh I.-H., Okoro A., Olagunju A.T., Olsen H.E., Olusanya B.O., Olusanya J.O., Ong K., Opio J.N., Oren E., Ortiz A., Osman M., Ota E., Mahesh P.A., Pacella R.E., Pakhale S., Pana A., Panda B.K., Jonas S., Papachristou C., Park E.-K., Patten S.B., Patton G.C., Paudel D., Paulson K., Pereira D.M., Perez-Ruiz F., Perico N., Pervaiz A., Petzold M., Phillips M.R., Pigott D.M., Pinho C., Plass D., Pletcher M.A., Polinder S., Postma M.J., Pourmalek F., Purcell C., Qorbani M., Radfar A., Rafay A., Rahimi-Movaghar V., Rahman M., Ur Rahman M.H., Rai R.K., Ranabhat C.L., Rankin Z., Rao P.C., Rath G.K., Rawaf S., Ray S.E., Rehm J., Reiner R.C., Reitsma M.B., Remuzzi G., Rezaei S., Rezai M.S., Rokni M.B., Ronfani L., Roshandel G., Roth G.A., Rothenbacher D., Ruhago G.M., Rizwan S.A., Saadat S., Sachdev P.S., Sadat N., Safdarian M., Saf S., Safiri S., Sagar R., Sahathevan R., Salama J., Salamati P., Salomon J.A., Samy A.M., Sanabria J.R., Sanchez-Niño M.D., Santomauro D., Santos I.S., Milicevic M.M.S., Sartorius B., Satpathy M., Shahraz S., Schmidt M.I., Schneider I.J.C., Schulhofer-Wohl S., Schutte A.E., Schwebel D.C., Schwendicke F., Sepanlou S.G., Servan-Mori E.E., Shackelford K.A., Shaikh M.A., Shamsipour M., Shamsizadeh M., Islam S.M.S., Sharma J., Sharma R., She J., Sheikhbahaei S., Shey M., Shi P., Shields C., Shigematsu M., Shiri R., Shirude S., Shiue I., Shoman H., Shrime M.G., Sigfusdottir I.D., Silpakit N., Silva J.P., Singh A., Singh J.A., Skiadaresi E., Sligar A., Smith A., Smith D.L., Smith M., Sobaih B.H.A., Soneji S., Sorensen R.J.D., Soriano J.B., Sreeramareddy C.T., Srinivasan V., Stanaway J.D., Stathopoulou V., Steel N., Stein D.J., Steiner C., Steinke S., Stokes M.A., Strong M., Strub B., Subart M., Sufyan M.B., Sunguya B.F., Sur P.J., Swaminathan S., Sykes B.L., Tabarés-Seisdedos R., Tadakamadla S.K., Takahashi K., Takala J.S., Talongwa R.T., Tarawneh M.R., Tavakkoli M., Taveira N., Tegegne T.K., Tehrani-Banihashemi A., Temsah M.-H., Terkawi A.S., Thakur J.S., Thamsuwan O., Thankappan K.R., Thomas K.E., Thompson A.H., Thomson A.J., Thrift A.G., Tobe-Gai R., Topor-Madry R., Torre A., Tortajada M., Towbin J.A., Tran B.X., Troeger C., Truelsen T., Tsoi D., Tuzcu E.M., Tyrovolas S., Ukwaja K.N., Undurraga E.A., Updike R., Uthman O.A., Uzochukwu B.S.C., Van Boven J.F.M., Vasankari T., Venketasubramanian N., Violante F.S., Vlassov V.V., Vollset S.E., Vos T., Wakayo T., Wallin M.T., Wang Y.-P., Weiderpass E., Weintraub R.G., Weiss D.J., Werdecker A., Westerman R., Whetter B., Whiteford H.A., Wijeratne T., Wiysonge C.S., Woldeyes B.G., Wolfe C.D.A., Woodbrook R., Workicho A., Xavier D., Xiao Q., Xu G., Yaghoubi M., Yakob B., Yano Y., Yaseri M., Yimam H.H., Yonemoto N., Yoon S.-J., Yotebieng M., Younis M.Z., Zaidi Z., El Sayed Zaki M., Zegeye E.A., Zenebe Z.M., Zerfu T.A., Zhang A.L., Zhang X., Zipkin B., Zodpey S., Lopez A.D., Murray C.J.L., GBD 2016 Causes of Death Collaborators (2017)
      Background: Monitoring levels and trends in premature mortality is crucial to understanding how societies can address prominent sources of early death. The Global Burden of Disease 2016 Study (GBD 2016) provides a comprehensive ...

    • Immunoglobulin D myeloma: Clinical features and outcome in the era of novel agents 

      Zagouri, F.; Kastritis, E.; Symeonidis, A. S.; Giannakoulas, N.; Katodritou, E.; Delimpasi, S.; Repousis, P.; Terpos, E.; Dimopoulos, M. A. (2014)
      Objectives: Immunoglobulin D (IgD) multiple myeloma is an uncommon variant of the disease probably associated with poorer prognosis. However, data on IgD myeloma patients treated in the novel agent era are lacking. Methods: ...

    • Immunohistochemicall expression of the p53, p21/Waf-1, Rb, p16 and Ki67 proteins in multiple myeloma 

      Kanavaros, P.; Stefanaki, K.; Vlachonikolis, J.; Papalazarou, D.; Rontogianni, D.; Arvanitis, D.; Antonakopoulos, G.; Gorgoulis, V.; Bai, M.; Agnantis, N. J. (2000)
      The aim of this study was to investigate the immunohistochemical expression of the proteins p53, Waf-l/p21, Rb, p16 and Ki67 in 38 cases of multiple myelomas (MM) and 4 cases of solitary extramedullary plasmacytomas in ...

    • Incidence of apoptosis and cell proliferation in multiple myeloma - Correlation with bcl-2 protein expression and serum levels of interleukin-6 (IL-6) and soluble IL-6 receptor 

      Chaidos, A. I.; Bai, M. C.; Kamina, S. A.; Kanavaros, P. E.; Agnantis, N. J.; Bourantas, K. L. (2002)
      We evaluated the in vivo incidence of apoptosis and cell proliferation in multiple myeloma (MM) and investigated the correlation of both cellular events with histological tumour stage and grade, bcl-2 protein expression, ...

    • Microvessel Density as a Surrogate Prognostic Marker in Patients with Multiple Myeloma: A Meta-Analysis 

      Ntellas P., Perivoliotis K., Dadouli K., Koukoulis G.K., Ioannou M. (2017)
      Bone marrow (BM) angiogenesis is considered a hallmark of multiple myeloma (MM) development and progression, and can be quantified with the use of microvessel density (MVD). The purpose of this study is to provide a review ...

    • The proteasome as a target for cancer treatment: Focus on bortezomib 

      Papandreou, C. N. (2005)
      Targeted degradation of key regulatory proteins is an essential element of cell-cycle control. The proteasome plays a pivotal role in the degradation of such proteins and has, therefore, become an important therapeutic ...

    • Real-world data on Len/Dex combination at second-line therapy of multiple myeloma: treatment at biochemical relapse is a significant prognostic factor for progression-free survival 

      Katodritou E., Kyrtsonis M.-C., Delimpasi S., Kyriakou D., Symeonidis A., Spanoudakis E., Vasilopoulos G., Anagnostopoulos A., Kioumi A., Zikos P., Aktypi A., Briasoulis E., Megalakaki A., Repousis P., Adamopoulos I., Gogos D., Kotsopoulou M., Pappa V., Papadaki E., Fotiou D., Nikolaou E., Giannopoulou E., Hatzimichael E., Giannakoulas N., Douka V., Kokoviadou K., Timotheatou D., Terpos E. (2018)
      We evaluated progression-free survival (PFS) rate of patients treated with lenalidomide/dexamethasone (Len/Dex), the efficacy of the combination, and the prognostic significance of treatment at biochemical vs. clinical ...

    • The role of marrow microenvironment in the growth and development of malignant plasma cells in multiple myeloma 

      Giannakoulas N., Ntanasis-Stathopoulos I., Terpos E. (2021)
      The development and effectiveness of novel therapies in multiple myeloma have been established in large clinical trials. However, multiple myeloma remains an incurable malignancy despite significant therapeutic advances. ...

    • The role of MTHFR gene in multiple myeloma 

      Zintzaras, E.; Giannouli, S.; Rodopoulou, P.; Voulgarelis, M. (2008)
      Case-control studies investigating associations between multiple myeloma (MM) and the C677T and A1298C polymorphisms of the methylenetetrahydrofolate reductase (MTHFR) have provided controversial results. In an attempt to ...

    • A systematic review and meta-analysis of interventional studies of bisphosphonates and denosumab in multiple myeloma and future perspectives 

      Chatziravdeli V., Katsaras G.N., Katsaras D., Doxani C., Stefanidis I., Zintzaras E. (2022)
      Bisphosphonates (BPs) and denosumab (DENOS), due to their ability to inhibit osteoclast activity, are used to prevent skeletal complications in multiple myeloma (MM) patients. The NCBI PubMed, Web of Science, Scopus and ...